We chatted to IronRidge Resources' CEO Vincent Mascolo who explains why the company has become a lithium explorer. Watch the video here.
After a solid start UK stocks sank into the red by Friday lunchtime, moving further away from recent records amid a blackout on Bloomberg computer terminals and new regulations in China on short-selling. Bloomberg's trading and information units are heavily relied upon by roughly 320,000 people arou
** Big currency swings are set to overshadow Q1 results at European drugmakers, with euro reporters helped by a 20% year-on-year move in the dollar/euro rate but companies accounting in dollars or Swiss francs held back ** Swiss franc reporters Actelion and Roche kick off the reporting sea
Stocks in London advanced on Friday morning on a quiet day for corporate newsflow, with investors awaiting key employment data from the UK while digesting Greek debt talks. "The FTSE opened the day on the positive side of flat, after yesterday afternoon's [...] declines pulled the index away from it
UK stock markets are set for a subdued start on Friday morning as investors focus on Greek debt talks on a quiet day for corporate news. City sources predict the FTSE 100 will open more or less flat on Thursday's close of 7,060.45. The index had pulled back the previous session from Wednesday's reco
Astrazeneca's eye cancer treatment, selumetinib, has been given 'orphan drug' status by US regulators, which should smooth its path to full approval. The product would be the first in the world to treat uveal melanoma, in which cancer cells form in eyeball tissue, with studies having found it makes
LONDON, April 17 (Reuters) - An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday. AZD9291, which the company expects to file for U.S. approval in the second quarter of 2015, is one o